Expression of calcium sensing receptor and E‐cadherin correlated with survival of lung adenocarcinoma

Thoracic Cancer

Liyuan Wen¹  Lichun Sun¹  Yuhui Xi²  Xuesong Chen¹  Ying Xing¹  Weiling Sun¹  Qingwei Meng¹ 

[1] The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China;Department of Pathophysiology, Harbin Medical University, Harbin, China

关键词: Calcium sensing receptor (CaSR);    E‐cadherin;    lung adenocarcinoma;    survival;   

DOI  :  10.1111/1759-7714.12255

来源: Wiley

【 摘 要 】

Abstract

Background

It has been reported that the calcium sensing receptor (CaSR), a widely expressed G protein-coupled receptor, can stimulate cell differentiation and proliferation. However, in malignant tumors, loss of CaSR expression has been associated with tumorigenesis, metastasis, and progression. Recent studies have indicated that the CaSR could promote the expression of E-cadherin, which was considered a tumor suppressor. However, in human lung adenocarcinoma, the importance of the CaSR and E-cadherin has not been sufficiently investigated.

Methods

Expression levels of CaSR and E-cadherin in paraffin sections from 117 resected lung adenocarcinoma patients were evaluated by immunohistochemistry. We analyzed the correlation between our target proteins and clinical variables. Clinical significance was analyzed by multivariate Cox regression analysis, Kaplan–Meier curve, and log-rank test.

Results

Expression of the CaSR in lung adenocarcinoma tissue was significantly lower than in the normal sample (P = 0.003). Kendall tau-b analysis showed that, in a lung adenocarcinoma sample, the expression of CaSR positively correlated with a high level of E-cadherin (P < 0.001). Lung adenocarcinoma patients with a strong expression of CaSR (P = 0.034) or E-cadherin (P = 0.001) had longer overall survival. Multivariate Cox proportional hazards model analysis showed that the combined marker was an independent prognostic indicator of overall survival (hazard ratio = 0.440, confidence interval = 0.249–0.779, P = 0.005).

Conclusions

We identified the CaSR as a new prognostic biomarker in lung adenocarcinoma. These results also suggested that the CaSR may become a new therapeutic target of lung adenocarcinoma.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Thoracic Cancer published by China Lung Oncology Group and Wiley Publishing Asia Pty Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.